NASDAQ:TPTX • US90041T1088
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TURNING POINT THERAPEUTICS I (TPTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-06-13 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-06-06 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2022-06-06 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-06-03 | Wedbush | Downgrade | Outperform -> Neutral |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-05-20 | B of A Securities | Initiate | Buy |
| 2022-05-11 | SVB Leerink | Maintains | Outperform |
| 2022-03-01 | Stifel | Maintains | Hold |
| 2022-02-10 | Wells Fargo | Maintains | Overweight |
| 2022-01-21 | Oppenheimer | Maintains | Outperform |
| 2021-12-07 | Cowen & Co. | Initiate | Outperform |
| 2021-11-10 | Oppenheimer | Maintains | Outperform |
| 2021-10-12 | HC Wainwright & Co. | Maintains | Buy |
| 2021-10-11 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2021-09-30 | Stifel | Initiate | Hold |
| 2021-04-06 | HC Wainwright & Co. | Maintains | Buy |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 25M | 30.829M 23.32% | 6.796M -77.96% | 38.715M 469.70% | 219.562M 467.13% | 538.142M 145.10% | 1.345B 150.00% | ||
| EBITDA YoY % growth | -77.23M -202.86% | -160.96M -108.42% | -236.791M -47.11% | -298.059M -25.87% | -283.09M 5.02% | -34.441M 87.83% | -49.443M -43.56% | -72.398M -46.43% | |
| EBIT YoY % growth | -77.72M -203.12% | -161.84M -108.23% | -238M -47.06% | -341.306M -43.41% | -391.863M -14.81% | -336.136M 14.22% | -328.57M 2.25% | -327.598M 0.30% | |
| Operating Margin | N/A | -647.36% | -772.00% | -5,022.38% | -1,012.17% | -153.09% | -61.06% | -24.35% | |
| EPS YoY % growth | -5.88 | -3.07 47.79% | -4.79 -56.03% | -6.85 -43.06% | -7.35 -7.26% | -5.30 27.86% | -5.73 -8.13% | -6.32 -10.30% |
| Q3 / 22 | Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.72 -28.64% | -1.77 -12.04% | -1.88 -25.12% | -1.96 -12.58% | -1.98 -14.79% | -1.98 -12.13% |
| Revenue Q2Q % growth | -100.00% | 5.051M | -100.00% | -100.00% | 4.82M | 11.858M 134.74% |
| EBITDA Q2Q % growth | -88.689M -34.77% | -49.909M 35.55% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -87.08M -30.65% | -90.058M -14.52% | -62.22M 16.97% | -100.47M 19.21% | -101.286M -16.31% | -98.124M -8.96% |
15 analysts have analysed TPTX and the average price target is 74.9 USD. This implies a price decrease of -1.46% is expected in the next year compared to the current price of 76.01.
TURNING POINT THERAPEUTICS I (TPTX) will report earnings on 2022-11-07.
The consensus EPS estimate for the next earnings of TURNING POINT THERAPEUTICS I (TPTX) is -1.72 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering TURNING POINT THERAPEUTICS I (TPTX) is 15.